146 related articles for article (PubMed ID: 37294534)
1. Virus infection participates in the occurrence and development of human diseases through monoamine oxidase.
Sun Y; Liu W; Luo B
Rev Med Virol; 2023 Sep; 33(5):e2465. PubMed ID: 37294534
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
3. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of the active site of brain monoamine oxidase.
Youdim MB
Monogr Neural Sci; 1980; 7():176-92. PubMed ID: 6785574
[TBL] [Abstract][Full Text] [Related]
5. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity.
Grimsby J; Zentner M; Shih JC
Life Sci; 1996; 58(9):777-87. PubMed ID: 8632725
[TBL] [Abstract][Full Text] [Related]
6. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.
Aljanabi R; Alsous L; Sabbah DA; Gul HI; Gul M; Bardaweel SK
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641563
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor design for monoamine oxidases.
Ramsay RR
Curr Pharm Des; 2013; 19(14):2529-39. PubMed ID: 23116392
[TBL] [Abstract][Full Text] [Related]
8. Properties of monoamine oxidase in monkey heart.
Katayama M; Kobayashi S; Oguchi K; Yasuhara H
Jpn J Pharmacol; 1984 Aug; 35(4):425-31. PubMed ID: 6438377
[TBL] [Abstract][Full Text] [Related]
9. The current status of monoamine oxidase and its inhibitors.
Jarrott B; Vajda FJ
Med J Aust; 1987 Jun; 146(12):634-8. PubMed ID: 3114597
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
11. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
Kumar B; Gupta VP; Kumar V
Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
[TBL] [Abstract][Full Text] [Related]
12. Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants.
Herraiz T; Flores A; Fernández L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():136-144. PubMed ID: 29268246
[TBL] [Abstract][Full Text] [Related]
13. Drugs related to monoamine oxidase activity.
Fišar Z
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
[TBL] [Abstract][Full Text] [Related]
14. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF
Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
[TBL] [Abstract][Full Text] [Related]
15. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Duarte P; Cuadrado A; León R
Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
[TBL] [Abstract][Full Text] [Related]
16. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents.
Herraiz T
J Enzyme Inhib Med Chem; 2012 Dec; 27(6):810-7. PubMed ID: 21992679
[TBL] [Abstract][Full Text] [Related]
18. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Garcia-Miralles M; Ooi J; Ferrari Bardile C; Tan LJ; George M; Drum CL; Lin RY; Hayden MR; Pouladi MA
Exp Neurol; 2016 Apr; 278():4-10. PubMed ID: 26825854
[TBL] [Abstract][Full Text] [Related]
20. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
Severina IS; Klimova GI; Nersisian AA
Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
